John R Prensner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5757597/publications.pdf

Version: 2024-02-01

37 papers	12,851 citations	126708 33 h-index	360668 35 g-index
39 all docs	39 docs citations	39 times ranked	20293 citing authors

#	Article	IF	Citations
1	The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics, 2015, 47, 199-208.	9.4	2,410
2	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	13.7	2,128
3	The Emergence of lncRNAs in Cancer Biology. Cancer Discovery, 2011, 1, 391-407.	7.7	1,612
4	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology, 2011, 29, 742-749.	9.4	950
5	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	2.3	608
6	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics, 2013, 45, 1392-1398.	9.4	601
7	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	5.8	378
8	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	3.8	333
9	Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers. Cell, 2012, 149, 1622-1634.	13.5	250
10	PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma. Cancer Research, 2012, 72, 1608-1613.	0.4	246
11	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.4	244
12	PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.4	237
13	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, The, 2014, 15, 1469-1480.	5.1	226
14	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Neoplasia, 2014, 16, 900-908.	2.3	216
15	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell, 2017, 171, 1559-1572.e20.	13.5	200
16	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	9.4	196
17	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications, 2016, 7, 12791.	5.8	196
18	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	7.7	191

#	Article	IF	Citations
19	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Research, 2011, 21, 1028-1041.	2.4	166
20	Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine, 2015, 21, 344-352.	15.2	165
21	The landscape of antisense gene expression in human cancers. Genome Research, 2015, 25, 1068-1079.	2.4	150
22	Metabolism unhinged: IDH mutations in cancer. Nature Medicine, 2011, 17, 291-293.	15.2	144
23	The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer. Molecular Cancer Research, 2014, 12, 1081-1087.	1.5	119
24	KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 1513-1522.	0.5	108
25	The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget, 2014, 5, 1434-1438.	0.8	106
26	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	7.7	91
27	Standardized annotation of translated open reading frames. Nature Biotechnology, 2022, 40, 994-999.	9.4	86
28	Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nature Biotechnology, 2021, 39, 697-704.	9.4	85
29	A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. Neoplasia, 2014, 16, 1121-1127.	2.3	81
30	Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nature Communications, 2013, 4, 2617.	5.8	71
31	Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatric Blood and Cancer, 2017, 64, e26288.	0.8	71
32	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	9.4	69
33	Oncogenic gene fusions in epithelial carcinomas. Current Opinion in Genetics and Development, 2009, 19, 82-91.	1.5	64
34	Systematic, evidence-based discovery of biomarkers at the NCI. Clinical and Experimental Metastasis, 2012, 29, 645-652.	1.7	22
35	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. JCO Precision Oncology, 2018, 2, 1-34.	1.5	10
36	A FIRE-y PAGE in the Computational Analysis of Cancer Profiles. Molecular Cell, 2009, 36, 732-733.	4.5	0

#	Article	IF	Citations
37	A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatric Blood and Cancer, 2021, 68, e28780.	0.8	0